Search
for
Sort by
Research 631–660 of 1000+
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- An Updated Etiology of Hair Loss and the New Cosmeceutical Paradigm in Therapy: Clearing ‘the Big Eight Strikes’
- Prostaglandin D <sub>2</sub> Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Clinical biochemistry of dihydrotestosterone
- Jojoba Oil: An Updated Comprehensive Review on Chemistry, Pharmaceutical Uses, and Toxicity
- Innate type 2 immunity controls hair follicle commensalism by Demodex mites
- Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
- Innovation and Biodiversity: Patent Trends in Therapeutic and Cosmetic Use of Scientifically Relevant Pantanal Plants
- Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
- Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
- 5 Alpha-Reductase Inhibitory Potential of Solanum nigrum Effective for Management of Alopecia
- Evidence Based Treatments of Alopecia Areata
- Managing patterned hair loss – a hair raising task!
- Dandruff lesional scalp skin exhibits epidermal T cell infiltration and a weakened hair follicle immune privilege
- Poster Presentations
- Discoid lupus erythematosus successfully treated with deucravacitinib
- EMULGEL EMERGENT SYSTEMS: AT A GLANCE FOR TOPICAL DRUG DELIVERY
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- <i>JAMA Dermatology—</i>The Year in Review, 2021
- Update on Hormonal Therapy in Hidradenitis Suppurativa
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Recomendaciones sobre el manejo clínico de la alopecia androgénica: un documento de consenso del Grupo Español de Tricología de la Academia Española de Dermatología y Venereología
- Skin manifestations associated with COVID-19
- Species Differences in Prostatic Steroid 5<i>α</i>-Reductases of Rat, Dog, and Human
- Anti-Androgen Effects of Extracts and Compounds from<i>Ganoderma lucidum</i>